AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8827134 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback in decision-making tasks
Number of subjects: 22
Study 8827134 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat stress (40 degrees C)
Number of subjects: 22
Study 1418778 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (250 mg every 6 h)
Number of subjects: 197
Study 1418778 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine + Acyclovir (800 mg every 6 h)
Number of subjects: 197
Study 1418778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 6396834 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose trimethoprim-sulfamethoxazole (4 tablets)
Number of subjects: 464
Study 6396834 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day trimethoprim-sulfamethoxazole (2 tablets twice daily)
Number of subjects: 464
Study 6396834 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day trimethoprim-sulfamethoxazole (2 tablets twice daily)
Number of subjects: 464
Study 30951148 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation 600 IU/d
Number of subjects: 0
Study 30951148 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation 2,000 IU/d
Number of subjects: 0
Study 30951148 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation 4,000 IU/d
Number of subjects: 0
Study 30951148 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29386058 — intervention group
Group type: EXPERIMENTAL
Intervention: Art integration using Caravaggio's paintings during the Ramsay sedation score lesson
Number of subjects: 22
Study 29386058 — intervention group
Group type: COMPARATOR
Intervention: Standard lesson without artistic support
Number of subjects: 22
Study 26466321 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance intervention group with increased dialysate glucose prescription
Number of subjects: 308
Study 26466321 — intervention group
Group type: COMPARATOR
Intervention: Control group (anuric patients in Shanghai)
Number of subjects: 308
Study 26466321 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonanuric BI intervention group (UK)
Number of subjects: 308
Study 26466321 — intervention group
Group type: COMPARATOR
Intervention: Active and control anuric patients (multilevel analysis)
Number of subjects: 308
Study 24480836 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) with tramadol and ketamine
Number of subjects: 75
Study 24480836 — intervention group
Group type: COMPARATOR
Intervention: Control group (tramadol and ketamine)
Number of subjects: 75
Study 22875560 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga and exercise (YEX)
Number of subjects: 14
Study 22875560 — intervention group
Group type: COMPARATOR
Intervention: Exercise only (EX)
Number of subjects: 14
Study 20052573 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal weight cone (VWC)
Number of subjects: 103
Study 20052573 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted pelvic floor muscle training (APFMT)
Number of subjects: 103
Study 18759805 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to structure patient-key worker communication
Number of subjects: 507
Study 15979851 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed reduction (CR)
Number of subjects: 45
Study 15979851 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 45
Study 15979851 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 45
Study 12534381 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraffin tulle gras (PTG) dressing
Number of subjects: 50
Study 12534381 — intervention group
Group type: COMPARATOR
Intervention: Nonadherent absorbable (NAA) dressing
Number of subjects: 50
Study 9501747 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (33.9 mg daily)
Number of subjects: 75
Study 9501747 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (162.5 mg daily)
Number of subjects: 75
Study 9501747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 7663312 — intervention group
Group type: EXPERIMENTAL
Intervention: ritanserin 5 mg/day
Number of subjects: 39
Study 7663312 — intervention group
Group type: EXPERIMENTAL
Intervention: ritanserin 10 mg/day
Number of subjects: 39
Study 7663312 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 39
Study 2624911 — intervention group
Group type: EXPERIMENTAL
Intervention: Keta tonometer
Number of subjects: 60
Study 2624911 — intervention group
Group type: COMPARATOR
Intervention: Goldmann tonometer
Number of subjects: 60
Study 630965 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (two large doses administered intravenously)
Number of subjects: 29
Study 630965 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 29
Study 30739259 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy (PAC) > 3 cycles
Number of subjects: 401
Study 30739259 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy (PAC) 1-3 cycles
Number of subjects: 401
Study 29368207 — intervention group
Group type: EXPERIMENTAL
Intervention: High cognitive and interpersonal risk group
Number of subjects: 467
Study 29368207 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cognitive and interpersonal risk group
Number of subjects: 467
Study 27655012 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) infusion (0.5 μg/kg per min for 4 h)
Number of subjects: 20
Study 27655012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25641309 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load motor control (LMC) exercise
Number of subjects: 70
Study 25641309 — intervention group
Group type: COMPARATOR
Intervention: High-load lifting (HLL) exercise
Number of subjects: 70
Study 23592833 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT defibrillator
Number of subjects: 111
Study 23592833 — intervention group
Group type: COMPARATOR
Intervention: Dual-chamber implantable cardioverter-defibrillator
Number of subjects: 111
Study 20579960 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 177
Study 20579960 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 177
Study 17925335 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol
Number of subjects: 180
Study 17925335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 16669955 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg alicaforsen
Number of subjects: 159
Study 16669955 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg alicaforsen
Number of subjects: 159
Study 16669955 — intervention group
Group type: COMPARATOR
Intervention: mesalazine
Number of subjects: 159
Study 12783912 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib, 25 mg once daily
Number of subjects: 351
Study 12783912 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen, 220 mg twice daily
Number of subjects: 351
Study 12783912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 10745280 — intervention group
Group type: EXPERIMENTAL
Intervention: Designer eggs enriched in vitamin E, lutein, selenium (Se), and docosahexaenoic acid (DHA)
Number of subjects: 40
Study 10745280 — intervention group
Group type: COMPARATOR
Intervention: Normal table eggs
Number of subjects: 40
Study 8931866 — intervention group
Group type: EXPERIMENTAL
Intervention: PAMBA 100-200 mg daily for 7 to 26 days with moderate corticosteroids (mean dose 36.1 mg prednisolone equivalent)
Number of subjects: 24
Study 8931866 — intervention group
Group type: COMPARATOR
Intervention: High-dose corticosteroids (mean 94.2 mg prednisolone equivalent) and immunosuppressive drugs
Number of subjects: 24
Study 1552109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 500
Study 1552109 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 500
Study 1552109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate with diphenhydramine premedication
Number of subjects: 500
Study 1552109 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol with diphenhydramine premedication
Number of subjects: 500
Study 2996580 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil (2 mg) by inhalation
Number of subjects: 8
Study 2996580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31021023 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) IL-6 levels in neurosarcoidosis patients
Number of subjects: 43
Study 31021023 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF CD4/CD8 ratio in neurosarcoidosis patients
Number of subjects: 43
Study 31021023 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF IL-6 levels in active vs. non-active neurosarcoidosis patients
Number of subjects: 43
Study 31021023 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF IL-6 concentration >50 pg/ml in neurosarcoidosis patients
Number of subjects: 43
Study 31021023 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IL-6 monoclonal antibody treatment in a refractory neurosarcoidosis patient
Number of subjects: 43
Study 31021023 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF IL-10 levels in neurosarcoidosis patients
Number of subjects: 43
Study 30312310 — intervention group
Group type: EXPERIMENTAL
Intervention: Running-related injuries (RRI)
Number of subjects: 140
Study 30312310 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial tibial stress syndrome (MTSS)
Number of subjects: 140
Study 30312310 — intervention group
Group type: EXPERIMENTAL
Intervention: Achilles tendinopathy (AT)
Number of subjects: 140
Study 30312310 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellofemoral pain (PFP)
Number of subjects: 140
Study 30312310 — intervention group
Group type: EXPERIMENTAL
Intervention: All types of injuries
Number of subjects: 140
Study 27004719 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartwatch
Number of subjects: 10
Study 27004719 — intervention group
Group type: COMPARATOR
Intervention: Smartphone
Number of subjects: 10
Study 25972024 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained eradication of Pseudomonas aeruginosa (Pa) after early antipseudomonal therapy
Number of subjects: 249
Study 25972024 — intervention group
Group type: COMPARATOR
Intervention: Nonsustained eradication of Pseudomonas aeruginosa (Pa) after early antipseudomonal therapy
Number of subjects: 249
Study 23392477 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative bile leakage test (sterile fat emulsion injected through the duct of the gallbladder)
Number of subjects: 107
Study 23392477 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods for treating the hepatic resection plane
Number of subjects: 107
Study 23392477 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative bile leakage test
Number of subjects: 107
Study 23392477 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods
Number of subjects: 107
Study 20435999 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard NexGen CR‐flex prosthesis
Number of subjects: 138
Study 20435999 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-specific NexGen CR‐flex prosthesis
Number of subjects: 138
Study 20435999 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 138
Study 18541884 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX‐4010 (high-concentration capsaicin patch)
Number of subjects: 307
Study 18541884 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX‐4010 (30-minute application)
Number of subjects: 307
Study 18541884 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX‐4010 (60-minute application)
Number of subjects: 307
Study 18541884 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX‐4010 (90-minute application)
Number of subjects: 307
Study 18541884 — intervention group
Group type: COMPARATOR
Intervention: Control (low-concentration capsaicin patch)
Number of subjects: 307
Study 18541884 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX‐4010
Number of subjects: 307
Study 18541884 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 307
Study 16028530 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant IFN‐alpha2 with complex immunoglobulin preparation (CIP) via rectal method
Number of subjects: 0
Study 16028530 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant IFN‐alpha2 with complex immunoglobulin preparation (CIP) via inhalation method
Number of subjects: 0
Study 12759839 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic intraocular lenses
Number of subjects: 0
Study 12759839 — intervention group
Group type: COMPARATOR
Intervention: PMMA intraocular lenses
Number of subjects: 0
Study 12759839 — intervention group
Group type: COMPARATOR
Intervention: Silicone intraocular lenses
Number of subjects: 0
Study 12759839 — intervention group
Group type: COMPARATOR
Intervention: Heparin coated PMMA intraocular lenses
Number of subjects: 0
Study 10078608 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus vaccination (Td) with primaquine prophylaxis
Number of subjects: 0
Study 10078608 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus vaccination (Td) with placebo prophylaxis
Number of subjects: 0
Study 10078608 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus vaccination (Td) with chloroquine prophylaxis
Number of subjects: 0
Study 10078608 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonimmunized)
Number of subjects: 0
Study 10078608 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid (TT) at low concentration (0.1 microg ml(‐1))
Number of subjects: 0
Study 7672149 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection with vigorous aspiration of oocyte cytoplasm
Number of subjects: 100
Study 3064266 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast preservation
Number of subjects: 0
Study 3064266 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 0
Study 29687620 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 0.5 mg
Number of subjects: 3900
Study 29687620 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 1.0 mg
Number of subjects: 3900
Study 29687620 — intervention group
Group type: COMPARATOR
Intervention: Semaglutide
Number of subjects: 3900
Study 28841431 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment (target SBP: 120 mmHg)
Number of subjects: 9361
Study 28841431 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure treatment (target SBP: 140 mmHg)
Number of subjects: 9361
Study 28841431 — intervention group
Group type: EXPERIMENTAL
Intervention: Low diastolic blood pressure (< 60 mmHg)
Number of subjects: 9361
Study 26226440 — intervention group
Group type: EXPERIMENTAL
Intervention: Doripenem
Number of subjects: 66
Study 26226440 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 66
Study 24130735 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo-suggestion (positive suggestion)
Number of subjects: 0
Study 24130735 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo-suggestion (negative suggestion)
Number of subjects: 0
Study 24130735 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-hypnotic imaginative suggestion
Number of subjects: 0
Study 24130735 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 0
Study 21418841 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Nissen fundoplication after esophagogastrostomy
Number of subjects: 70
Study 21418841 — intervention group
Group type: COMPARATOR
Intervention: Esophagogastrostomy with stapler only (Control group)
Number of subjects: 70
Study 18923231 — intervention group
Group type: EXPERIMENTAL
Intervention: Celacade therapy
Number of subjects: 0
Study 20389253 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK surgery
Number of subjects: 20
Study 16139717 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-containing cement
Number of subjects: 90
Study 16139717 — intervention group
Group type: COMPARATOR
Intervention: Palacos with gentamicin (Control)
Number of subjects: 90
Study 11925376 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (multiple low-dose 0.25 mg and single high-dose 3 mg)
Number of subjects: 0
Study 11925376 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Number of subjects: 0
Study 11925376 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist and GnRH agonist (long protocol)
Number of subjects: 0
Study 9593172 — intervention group
Group type: EXPERIMENTAL
Intervention: WR 238605, a single oral dose of 600 mg administered 1 day prior to challenge
Number of subjects: 4
Study 8169182 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (CZP) up to 2 mg/day for 4 weeks
Number of subjects: 15
Study 8169182 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 15
Study 8169182 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (CZP)
Number of subjects: 15
Study 3198992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (10 mg IV as bolus)
Number of subjects: 14
Study 3198992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 12215318 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/day
Number of subjects: 18
Study 12215318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29030710 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar hip arthroplasty (BHA)
Number of subjects: 42
Study 29030710 — intervention group
Group type: COMPARATOR
Intervention: Total hip replacement (THR)
Number of subjects: 42
Study 26577691 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) monotherapy (50 mg/m²/day for 10 days)
Number of subjects: 47
Study 26577691 — intervention group
Group type: COMPARATOR
Intervention: Azacitidine (AZA) + Entinostat (4 mg/m²/day on days 3 and 10)
Number of subjects: 47
Study 25034515 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed artificial insemination (TAI) protocol starting at 12 days after P4 device removal
Number of subjects: 774
Study 25034515 — intervention group
Group type: COMPARATOR
Intervention: Timed artificial insemination (TAI) protocol starting at 10 days after P4 device removal
Number of subjects: 774
Study 25034515 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed artificial insemination (TAI) protocol starting at 14 days after P4 device removal
Number of subjects: 774
Study 25034515 — intervention group
Group type: EXPERIMENTAL
Intervention: Final pregnancy rate across all groups
Number of subjects: 774
Study 22378225 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrates (2% of energy intake) replacing fat
Number of subjects: 25943
Study 22378225 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrates (2% of energy intake) replacing protein
Number of subjects: 25943
Study 22378225 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-GI carbohydrates replacing total fat
Number of subjects: 25943
Study 22378225 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-, medium-, or high-GI carbohydrates replacing total, meat, or milk protein
Number of subjects: 25943
Study 20152561 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel tapering regimen for 4 weeks
Number of subjects: 69
Study 20152561 — intervention group
Group type: COMPARATOR
Intervention: Continued daily clopidogrel intake for 4 more weeks
Number of subjects: 69
Study 18805757 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B nasal spray (5 mg/ml)
Number of subjects: 30
Study 18805757 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray (lacking amphotericin B)
Number of subjects: 30
Study 16136470 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose nevirapine
Number of subjects: 32
Study 12186600 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo, 40 mg 3 times per day (n = 115)
Number of subjects: 230
Study 12186600 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 115)
Number of subjects: 230
Study 12186600 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo
Number of subjects: 230
Study 12186600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 10540009 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth Occlusion Pressure (MOP)
Number of subjects: 28
Study 10540009 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Testing (ET)
Number of subjects: 28
Study 10540009 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal Inspiratory Pressure (PI(max))
Number of subjects: 28
Study 10540009 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak Expiratory Pressure (PE(max))
Number of subjects: 28
Study 10540009 — intervention group
Group type: EXPERIMENTAL
Intervention: Norris Spinal Score (SNS)
Number of subjects: 28
Study 10540009 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulbar Score (BNS)
Number of subjects: 28
Study 10540009 — intervention group
Group type: EXPERIMENTAL
Intervention: MOP slope
Number of subjects: 28
Study 7599728 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage surgery
Number of subjects: 44
Study 7599728 — intervention group
Group type: COMPARATOR
Intervention: Two-stage surgery
Number of subjects: 44
Study 7599728 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage surgery (subsequent consecutive group)
Number of subjects: 44
Study 7599728 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall one-stage surgeries
Number of subjects: 44
Study 7599728 — intervention group
Group type: COMPARATOR
Intervention: Overall two-stage surgeries
Number of subjects: 44
Study 2092029 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine 40 mg
Number of subjects: 40
Study 2092029 — intervention group
Group type: COMPARATOR
Intervention: ranitidine 300 mg
Number of subjects: 40
Study 897855 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.5 mg injected intramuscularly half an hour before the meal
Number of subjects: 63
Study 897855 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg injected intramuscularly half an hour before the meal
Number of subjects: 63
Study 897855 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (no intervention)
Number of subjects: 63